newsfilter
← Latest News
GlobeNewswire·

Scribe Therapeutics to Participate in Upcoming Investor Conferences

  • Scribe Therapeutics Inc. (NASDAQ: SCTX) announced management participation in three upcoming investor conferences.
  • CEO Benjamin Oakes, Ph.D., will join a fireside chat at the Wells Fargo Healthcare Conference in Boston on Sept. 9, 2026.
  • CEO Benjamin Oakes, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 15, 2026.
  • CFO David Parrot, M.B.A., will deliver an Innovation Spotlight presentation at the Cell & Gene Meeting on the Mesa in Phoenix on Oct. 5, 2026.
  • The company focuses on engineering in vivo CRISPR technologies to prevent disease & extend healthy lifespan, starting with cardiometabolic conditions.
  • Scribe's lead candidate STX-1150 is a liver-targeted therapy designed to epigenetically silence the PCSK9 gene & reduce LDL-C without permanent DNA changes.
  • Scribe has formed strategic collaborations with Sanofi & Eli Lilly to advance its CRISPR by Design™ approach.
  • The company was co-founded by Nobel Prize winner Jennifer Doudna & aims to make genetic medicines a standard of care for highly prevalent diseases.